相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Alzheimer's disease: clinical trials and drug development (vol 9, pg 702, 2010)
F. Mangialasche et al.
LANCET NEUROLOGY (2011)
A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease
Ronald S. Black et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2010)
Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease
Kaj Blennow et al.
Alzheimers & Dementia (2010)
Modulation of tau pathology in tau transgenic models
Jean-Pierre Brion et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2010)
The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia
Jessica M. Mc Donald et al.
BRAIN (2010)
Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease
James A. Duce et al.
CELL (2010)
Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid beta After a Single Administration of an Amyloid beta Monoclonal Antibody in Subjects With Alzheimer Disease
Eric R. Siemers et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Abeta DNA Vaccination for Alzheimer's Disease: Focus on Disease Prevention
David H. Cribbs
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2010)
Towards Disease-Modifying Treatment of Alzheimer's Disease: Drugs Targeting β-Amyloid
V. Frisardi et al.
CURRENT ALZHEIMER RESEARCH (2010)
β-Amyloid: A Disease Target or a Synaptic Regulator Affecting Age-Related Neurotransmitter Changes?
E. Mura et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Neurotoxicity of beta-Amyloid Protein: Oligomerization, Channel Formation and Calcium Dyshomeostasis
Masahiro Kawahara
CURRENT PHARMACEUTICAL DESIGN (2010)
Bapineuzumab
Geoffrey A. Kerchner et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses
Noel G. Faux et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne et al.
LANCET NEUROLOGY (2010)
Alzheimer's disease: strategies for disease modification
Martin Citron
NATURE REVIEWS DRUG DISCOVERY (2010)
Can Alzheimer disease be prevented by amyloid-β immunotherapy?
Cynthia A. Lemere et al.
NATURE REVIEWS NEUROLOGY (2010)
ADDLs and the signaling web that leads to Alzheimer's disease
Grant A. Krafft et al.
NEUROPHARMACOLOGY (2010)
Tau Reduction Prevents Aβ-Induced Defects in Axonal Transport
Keith A. Vossel et al.
SCIENCE (2010)
Immunization Therapy for Alzheimer Disease: A Comprehensive Review of Active Immunization Strategies
Takeshi Tabira
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Alzheimer's disease: clinical trials and drug development
Francesca Mangialasche et al.
LANCET NEUROLOGY (2010)
Identification, characterization, and comparison of amino-terminally truncated Aβ 42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment
Ronald B. DeMattos et al.
Alzheimers & Dementia (2009)
Selection of an anti-Abeta antibody that binds various forms of Abeta and blocks toxicity both in vitro and in vivo
Ryan J. Watts et al.
Alzheimers & Dementia (2009)
Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer's disease
Timothy Nicholas et al.
Alzheimers & Dementia (2009)
Drug Development for Alzheimer's Disease: Where Are We Now and Where Are We Headed?
Marwan N. Sabbagh
AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY (2009)
Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease
John C. Morris et al.
ARCHIVES OF NEUROLOGY (2009)
Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo
G. D. Rabinovici et al.
BEHAVIOURAL NEUROLOGY (2009)
Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
Bruno Vellas et al.
CURRENT ALZHEIMER RESEARCH (2009)
Disease-Modifying Approach to the Treatment of Alzheimer's Disease From alpha-Secretase Activators to gamma-Secretase Inhibitors and Modulators
Francesco Panza et al.
DRUGS & AGING (2009)
Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?
Gregory A. Jicha
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Vaccination with Aβ-Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral Aβ and Lowers Plaque Burden in APP Transgenic Mice
Patricia Bach et al.
JOURNAL OF IMMUNOLOGY (2009)
Aβ Immunotherapy: Intracerebral Sequestration of Aβ by an Anti-Aβ Monoclonal Antibody 266 with High Affinity to Soluble Aβ
Kaoru Yamada et al.
JOURNAL OF NEUROSCIENCE (2009)
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Norman R. Relkin et al.
NEUROBIOLOGY OF AGING (2009)
Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls
N. M. Scheinin et al.
NEUROLOGY (2009)
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2009)
The Role of Apolipoprotein E in Alzheimer's Disease
Jungsu Kim et al.
NEURON (2009)
Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease: drugs targeting β-amyloid and tau protein
Francesco Panza et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2009)
S1-02-02: Natural human antibodies targeting amyloid aggregates in intravenous immunoglobulin
Norman R. Relkin
Alzheimers & Dementia (2008)
P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease
Eric R. Siemers et al.
Alzheimers & Dementia (2008)
Active and passive immunotherapy for Neurodegenerative disorders
David L. Brody et al.
ANNUAL REVIEW OF NEUROSCIENCE (2008)
Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer's disease
Jung Won Youm et al.
BIOTECHNOLOGY LETTERS (2008)
Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools
Peter Lichtlen et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Alzheimer disease pathology as a host response
Rudy J. Castellani et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2008)
Immunotherapy reduces vascular amyloid-β in PDAPP mice
Sally Schroeter et al.
JOURNAL OF NEUROSCIENCE (2008)
Long-term effects of Aβ42 immunisation in Alzheimer's disease:: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes et al.
LANCET (2008)
Amyloid-beta immunisation for Alzheimer's disease
Thomas Wisniewski et al.
LANCET NEUROLOGY (2008)
Antibody capture of soluble A beta does not reduce cortical A beta amyloidosis in the PDAPP mouse
Peter Seubert et al.
NEURODEGENERATIVE DISEASES (2008)
Progress in the active immunotherapeutic approach to Alzheimer's disease: Clinical investigations into AN1792-Associated meningoencephalitis
Michael Pride et al.
NEURODEGENERATIVE DISEASES (2008)
Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine - A Novel Immunotherapeutic Strategy
Nina Movsesyan et al.
PLOS ONE (2008)
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Aβ species in amyloid precursor protein transgenic mice
Irina Petrushina et al.
JOURNAL OF NEUROSCIENCE (2007)
The epidemiology of the dementias: an update
Chengxuan Qiu et al.
CURRENT OPINION IN PSYCHIATRY (2007)
Forecasting the global burden of Alzheimer's disease
Ron Brookmeyer et al.
ALZHEIMERS & DEMENTIA (2007)
Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice
Andreas Muhs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Absence of β-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia
Stephanie Bombois et al.
ARCHIVES OF NEUROLOGY (2007)
Transcutaneous β-amyloid immunization reduces cerebral β-amyloid deposits without T cell infiltration and microhemorrhage
William V. Nikolic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid
D. M. Wilcock et al.
NEUROSCIENCE (2007)
Amyloid-β peptide remnants in AN-1792-immunized Alzheimer's disease patients -: A biochemical analysis
R. Lyle Patton et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Lipid metabolism in cognitive decline and dementia
Francesco Panza et al.
BRAIN RESEARCH REVIEWS (2006)
Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-β peptide
Gili Istrin et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2006)
Nonviral Aβ DNA vaccine therapy against Alzheimer's disease:: Long-term effects and safety
Yoshio Okura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Antibodies against β-amyloid reduce Aβ oligomers, glycogen synthase kinase-3β activation and τ phosphorylation in vivo and in vitro
QL Ma et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2006)
The cerebral beta-amyloid angiopathies: Hereditary and sporadic
SX Zhang-Nunes et al.
BRAIN PATHOLOGY (2006)
Neuropathology of Alzheimer disease: pathognomonic but not pathogenic
Rudy J. Castellani et al.
ACTA NEUROPATHOLOGICA (2006)
Transgenic potato expressing Aβ reduce Aβ burden in Alzheimer's disease mouse model
JW Youm et al.
FEBS LETTERS (2005)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S Gilman et al.
NEUROLOGY (2005)
HSV amplicon-mediated Aβ vaccination in Tg2576 mice:: differential antigen-specific immune responses
WJ Bowers et al.
NEUROBIOLOGY OF AGING (2005)
Mechanisms of A beta Plaque Clearance following Passive A beta Immunization
Dave Morgan
NEURODEGENERATIVE DISEASES (2005)
Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide
MG Agadjanyan et al.
JOURNAL OF IMMUNOLOGY (2005)
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor proteintransgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β
MM Racke et al.
JOURNAL OF NEUROSCIENCE (2005)
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
AJ Bayer et al.
NEUROLOGY (2005)
Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease
E Masliah et al.
NEUROLOGY (2005)
Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease
RC Dodel et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome
S Oddo et al.
NEURON (2004)
An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives
EM Sigurdsson et al.
JOURNAL OF NEUROSCIENCE (2004)
Oligomers in the brain: The emerging role of soluble protein aggregates in neurodegeneration
DM Walsh et al.
PROTEIN AND PEPTIDE LETTERS (2004)
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease
I Ferrer et al.
BRAIN PATHOLOGY (2004)
Lessons from the AN 1792 Alzheimer vaccine:: lest we forget
SR Robinson et al.
NEUROBIOLOGY OF AGING (2004)
Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply
CS Atwood et al.
BRAIN RESEARCH REVIEWS (2003)
Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity
YS Du et al.
BRAIN (2003)
Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease
C Hock et al.
NEURON (2003)
Reduction of β-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization
D Frenkel et al.
VACCINE (2003)
Neuropathology of cognitively normal elderly
DS Knopman et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2003)
A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease
JM Zhang et al.
NEUROBIOLOGY OF DISEASE (2003)
Cerebral hemorrhage after passive anti-Aβ immunotherapy
M Pfeifer et al.
SCIENCE (2002)
Nasal vaccination with β-amyloid peptide for the treatment of Alzheimer's disease
CA Lemere et al.
DNA AND CELL BIOLOGY (2001)
The cell biology of Alzheimer's disease: uncovering the secrets of secretases
J Walter et al.
CURRENT OPINION IN NEUROBIOLOGY (2001)
Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils
J Götz et al.
SCIENCE (2001)
Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice
EM Sigurdsson et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
RB DeMattos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy
BJ Backskai et al.
NATURE MEDICINE (2001)
Redox-active iron mediates amyloid-β toxicity
CA Rottkamp et al.
FREE RADICAL BIOLOGY AND MEDICINE (2001)
Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides
DT Laskowitz et al.
EXPERIMENTAL NEUROLOGY (2001)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)